Montelukast Ratiopharm (Montelukast Sodium)

Montelukast selectively antagonises the cysteinyl leukotriene receptor CysLT1, blocking the action of leukotrienes that cause airway smooth‑muscle constriction, mucus production and inflammatory cell recruitment. This results in decreased bronchoconstriction and reduced inflammation of the respiratory tract.

The dosage of Montelukast Ratiopharm is determined by the prescribing clinician based on the patient’s age, weight, indication and clinical response. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed; patients should follow the prescriber’s instructions exactly.

The pregnancy category for Montelukast is not definitively established, and limited data are available. It should only be used during pregnancy or lactation if the potential benefit justifies any potential risk to the fetus or infant. The prescriber will evaluate individual circumstances before recommending therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is especially useful for patients who prefer oral therapy or have aspirin‑exacerbated respiratory disease. While inhaled steroids target a broader range of inflammatory pathways, Montelukast specifically blocks leukotriene‑mediated effects.

Montelukast Ratiopharm tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally as a whole tablet, with or without food, according to the prescriber’s directions. Swallow the tablet whole; do not crush, chew, or split it unless specifically instructed by a healthcare professional.

Serious adverse events, although rare, include severe allergic reactions such as rash, angioedema or anaphylaxis, and neuropsychiatric effects like depression, suicidal thoughts, or behavioural changes. Hepatic enzyme elevations and rare skin disorders such as Stevens‑Johnson syndrome have also been reported. Prompt medical attention is required if any of these occur.

Montelukast Ratiopharm is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Caution is advised for patients with severe hepatic impairment, and it should be used only under close supervision in those with a history of psychiatric disorders.